
Kluwer Patent Blog

Dosage Regimen, European Patent Office (EPO Enlarged Board of Appeal), 19 February 2010

Bart van Weezenbeek · Friday, February 19th, 2010 · Landmark European Patent Cases

The Enlarged Board of Appeal answers three questions of law as follows:

Question 1: Where it is already known to use a medicament to treat an illness, Article 54(5) EPC does not exclude that this medicament be patented for use in a different treatment by therapy of the same illness.

Question 2: Such patenting is also not excluded where a dosage regime is the only feature claimed which is not comprised in the state of the art.

Question 3: Where the subject-matter of a claim is rendered novel only by a new therapeutic use of a medicament, such claim may no longer have the format of a so called Swiss-type claim as instituted by decision G 5/83. This type of claim has been ruled forbidden in the short future for any new application filed after three months from the date of publication of the present decision in the Official Journal of the EPO.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how [Kluwer IP Law](#) can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change

This entry was posted on Friday, February 19th, 2010 at 2:57 am and is filed under [Biologics](#), [Case Law](#), [EPC](#), [Exceptions to patentability](#), [Industrial application](#), [Opposition](#), [Second Medical Use](#). You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.